Inventor · disambiguated record
James Bernard Kramer
Also filed as: KRAMER JAMES B · KRAMER JAMES BERNARD
37 granted patents·9 pending applications·458 citations·filing 1989–2023
97Inventor score
Files withCAYMAN CHEMICAL CO INC17WARNER LAMBERT CO17AKOS BIOSCIENCES INC3THESAN PHARMACEUTICALS INC3BARRETT STEPHEN D1
Top patents by PatentIndex Score
46 records- 0196US5990146ABenzimidazoles for inhibiting protein tyrosine kinase mediated cellular proliferationWARNER LAMBERT CO·Filed 1998·Granted Nov 23, 1999·92 cites·9 claims
- 0296US4981865AN-hydroxyamide, N-hydroxythioamide, hydroxyurea, and N-hydroxythiourea derivatives of selected nsaids as antiinflammatory agentsWARNER LAMBERT CO·Filed 1989·Granted Jan 1, 1991·57 cites·22 claims
- 0391US5434188A1-ether and 1-thioether-naphthalene-2-carboxamides as inhibitors of cell adhesion and as inhibitors of the activation of HIVWARNER LAMBERT CO·Filed 1994·Granted Jul 18, 1995·48 cites·11 claims
- 0490US5350748A3-thio or amino substituted-benzo[b]thiophene-2-carboxamides and 3-oxygen, thio, or amino substituted-benzofuran-2-carboxamides as inhibitors of cell adhesionWARNER LAMBERT CO·Filed 1993·Granted Sep 27, 1994·44 cites·3 claims
- 0587US11660348B1Cannabinoid conjugate moleculesAKOS BIOSCIENCES INC·Filed 2022·Granted May 30, 2023·2 cites·8 claims
- 0687US5112846AN-hydroxyamide, N-hydroxythioamide, hydroxyurea, and N-hydroxythiourea derivatives of selected nsaids as antiinflammatory agentsWARNER LAMBERT CO·Filed 1990·Granted May 12, 1992·28 cites·23 claims
- 0786US9487478B2Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditionsCAYMAN CHEMICAL CO INC·Filed 2015·Granted Nov 8, 2016·4 cites·21 claims
- 0885US9180116B2Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditionsCAYMAN CHEMICAL CO INC·Filed 2013·Granted Nov 10, 2015·6 cites·20 claims
- 0983US5075330AN-hydroxyamide, N-hydroxythioamide, N-hydroxyurea, and N-hydroxythiourea derivatives of selected NSAIDS as antiinflammatory agentsWARNER LAMBERT CO·Filed 1990·Granted Dec 24, 1991·21 cites·9 claims
- 1082US9440919B2Difluorolactam compositions for EP4-mediated osteo related diseases and conditionsCAYMAN CHEMICAL CO INC·Filed 2013·Granted Sep 13, 2016·4 cites·23 claims
- 1182US7169778B2Pteridinones as kinase inhibitorsWARNER LAMBERT CO·Filed 2000·Granted Jan 30, 2007·15 cites·7 claims
- 1280US9701630B2Difluorolactam compositions for EP4-mediated osteo related diseases and conditionsCAYMAN CHEMICAL CO INC·Filed 2016·Granted Jul 11, 2017·2 cites·20 claims
- 1380US9260450B2Therapeutic pyrazolyl thienopyridinesTHESAN PHARMACEUTICALS INC·Filed 2015·Granted Feb 16, 2016·2 cites·12 claims
- 1479US7022711B22-(4-Pyridyl)amino-6-dialkoxyphenyl-pyrido[2,3-d]pyrimidin-7-onesWARNER LAMBERT CO·Filed 2001·Granted Apr 4, 2006·12 cites·20 claims
- 1578US7964612B2Therapeutic pyrazolyl thienopyridinesGRACEWAY PHARMACEUTICALS LLC·Filed 2007·Granted Jun 21, 2011·2 cites·12 claims
- 1677US11884624B2Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditionsCAYMAN CHEMICAL CO INC·Filed 2021·Granted Jan 30, 2024·0 cites·3 claims
- 1777US8455512B2Therapeutic pyrazolyl thienopyridinesBARRETT STEPHEN D·Filed 2011·Granted Jun 4, 2013·4 cites·11 claims
- 1874US11944686B2Cannabinoid conjugate moleculesAKOS BIOSCIENCES INC·Filed 2023·Granted Apr 2, 2024·0 cites·4 claims
- 1974US6218388B1Benzimidazoles for inhibiting protein tyrosine kinase mediated cellular proliferationWARNER LAMBERT CO·Filed 1999·Granted Apr 17, 2001·37 cites·7 claims
- 2073US11066361B2Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditionsCAYMAN CHEMICAL CO INC·Filed 2020·Granted Jul 20, 2021·0 cites·3 claims
- 2172US8536185B2Multiheteroaryl compounds as inhibitors of H-PGDS and their use for treating prostaglandin D2 mediated diseasesENDRES GREGORY W·Filed 2009·Granted Sep 17, 2013·2 cites·57 claims
- 2271US11883499B2Cannabinoid conjugate moleculesAKOS BIOSCIENCES INC·Filed 2022·Granted Jan 30, 2024·0 cites·7 claims
- 2367US10556862B2Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditionsCAYMAN CHEMICAL CO INC·Filed 2018·Granted Feb 11, 2020·0 cites·4 claims
- 2466US11345690B2Methods of synthesizing a difluorolactam analogCAYMAN CHEMICAL CO INC·Filed 2019·Granted May 31, 2022·0 cites·3 claims
- 2566US5571825AMethod of selectively inhibiting prostaglandin G/H synthase-2WARNER LAMBERT CO·Filed 1995·Granted Nov 5, 1996·30 cites·10 claims
- 2665US6683183B2Pyridotriazines and pyridopyridazinesWARNER LAMBERT CO·Filed 2001·Granted Jan 27, 2004·2 cites·23 claims
- 2761US9090625B2Therapeutic pyrazolyl thienopyridinesTHESAN PHARMACEUTICALS INC·Filed 2013·Granted Jul 28, 2015·0 cites·18 claims
- 2860US9914725B2Methods of synthesizing a difluorolactam analogCAYMAN CHEMICAL CO INC·Filed 2014·Granted Mar 13, 2018·0 cites·4 claims
- 2959US2017066751A1Difluorolactam compounds as ep4 receptor-selective agonists for use in the treatment of ep4-mediated diseases and conditionsCAYMAN CHEMICAL CO INC·Filed 2016·Application pending·0 cites
- 3058US9126973B2Multiheteroaryl compounds as inhibitors of H-PGDS and their use for treating prostaglandin D2 mediated diseasesCAYMAN CHEMICAL CO INC·Filed 2014·Granted Sep 8, 2015·0 cites·51 claims
- 3158US7501425B1Bicyclic pyrimidines and bicyclic 3,4-dihydropyprimidines as inhibitors of cellular proliferationWARNER LAMBERT CO·Filed 1999·Granted Mar 10, 2009·15 cites·36 claims
- 3258US5102897A3,5-ditertiarybutyl-4-hydroxyphenyl, 1,3,4-thiadiazoles and oxadiazoles linked by carbon, oxygen, and sulfur residuesWARNER LAMBERT CO·Filed 1991·Granted Apr 7, 1992·12 cites·23 claims
- 3358US2024174631A1Compounds, compositions, and methods for modulating fgf activityRECOVERY THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 3457US9938289B2Therapeutic pyrazolyl thienopyridinesTHESAN PHARMACEUTICALS INC·Filed 2016·Granted Apr 10, 2018·0 cites·17 claims
- 3556US5565446ABenzothiophene, benzofuran and indole-thiazepinones, oxazepinones and diazepinones as inhibitors of cell adhesion and as inhibitors of HIVWARNER LAMBERT CO·Filed 1995·Granted Oct 15, 1996·11 cites·12 claims
- 3655US2019144435A1Difluorolactam compositions for ep4-mediated osteo related diseases and conditionsCAYMAN CHEMICAL CO INC·Filed 2019·Application pending·0 cites
- 3754US2018170918A1Methods of synthesizing a difluorolactam analogCAYMAN CHEMICAL CO INC·Filed 2018·Application pending·0 cites
- 3854US2007049600A1Pteridinones as kinase inhibitorsWARNER LAMBERT CO·Filed 2006·Application pending·0 cites
- 3953US2017260173A1Difluorolactam compositions for ep4-mediated osteo related diseases and condtionsCAYMAN CHEMICAL CO INC·Filed 2017·Application pending·0 cites
- 4053US2013079375A1Multiheteroaryl compounds as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseasesCAYMAN CHEMICAL CO INC·Filed 2012·Application pending·0 cites
- 4153US2025051286A1Small molecule inhibitors of pr3 and hne and uses thereofORIXA THERAPEUTICS LLC·Filed 2022·Application pending·0 cites
- 4249US10729810B2Methods, systems, and compositions for promoting bone growthCAYMAN CHEMICAL CO INC·Filed 2014·Granted Aug 4, 2020·0 cites·16 claims
- 4344US5489586AMethod for treating inflammatory disease in humansWARNER LAMBERT CO·Filed 1994·Granted Feb 6, 1996·4 cites·4 claims
- 4444US5442111A3,5-di-tetriary-4-butyl-4-hydroxyphenyloxy- or tioalkylene N-hydroxyamides, N-hydroxythioamides, N-hydroxyureas, and N-hydroxythioureas as 5-lipoxygenase inhibitorsWARNER LAMBERT CO·Filed 1991·Granted Aug 15, 1995·2 cites·2 claims
- 4542US9688627B2Lactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditionsCAYMAN CHEMICAL CO INC·Filed 2014·Granted Jun 27, 2017·0 cites·24 claims
- 4641US2004044012A1Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferationFiled 2003·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when James Bernard Kramer files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →